{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T10:42:35Z","timestamp":1795084955275,"version":"4.10.2"},"reference-count":46,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,5,14]]},"abstract":"<jats:p>Although rituximab is a key molecular targeting drug for CD20-positive B-cell lymphomas, resistance to rituximab has recently been recognized as a considerable problem. Here, we report that a CD20-negative phenotypic change after chemotherapies with rituximab occurs in a certain number of CD20-positive B-cell lymphoma patients. For 5 years, 124 patients with B-cell malignancies were treated with rituximab-containing chemotherapies in Nagoya University Hospital. Relapse or progression was confirmed in 36 patients (29.0%), and a rebiopsy was performed in 19 patients. Of those 19, 5 (26.3%; diffuse large B-cell lymphoma [DLBCL], 3 cases; DLBCL transformed from follicular lymphoma, 2 cases) indicated CD20 protein-negative transformation. Despite salvage chemotherapies without rituximab, all 5 patients died within 1 year of the CD20-negative transformation. Quantitative reverse-transcription\u2013polymerase chain reaction (RT-PCR) showed that CD20 mRNA expression was significantly lower in CD20-negative cells than in CD20-positive cells obtained from the same patient. Interestingly, when CD20-negative cells were treated with 5-aza-2\u2032-deoxycytidine in vitro, the expression of CD20 mRNA was stimulated within 3 days, resulting in the restoration of both cell surface expression of the CD20 protein and rituximab sensitivity. These findings suggest that some epigenetic mechanisms may be partly related to the down-regulation of CD20 expression after rituximab treatment.<\/jats:p>","DOI":"10.1182\/blood-2008-08-175208","type":"journal-article","created":{"date-parts":[[2009,2,26]],"date-time":"2009-02-26T21:59:33Z","timestamp":1235685573000},"page":"4885-4893","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":225,"title":["Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance"],"prefix":"10.1182","volume":"113","author":[{"given":"Junji","family":"Hiraga","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya;"},{"name":"Department of Hematology, Toyota Memorial Hospital, Toyota;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tomita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Pathology, Japanese Red Cross, Nagoya First Hospital, Nagoya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology and Clinical Laboratories, Nagoya University Hospital, Nagoya; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagoya University School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111614154465400_B1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1053\/j.seminoncol.2006.01.024","article-title":"Monoclonal antibody therapy for B-cell malignancies.","volume":"33","author":"Cheson","year":"2006","journal-title":"Semin Oncol"},{"key":"2019111614154465400_B2","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer.","volume":"6","author":"Imai","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"2019111614154465400_B3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2019111614154465400_B4","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111614154465400_B5","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","article-title":"Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).","volume":"108","author":"Forstpointner","year":"2006","journal-title":"Blood"},{"key":"2019111614154465400_B6","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111614154465400_B7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","article-title":"CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.","volume":"7","author":"Pfreundschuh","year":"2006","journal-title":"Lancet Oncol"},{"key":"2019111614154465400_B8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdf155","article-title":"Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.","volume":"13","author":"Igarashi","year":"2002","journal-title":"Ann Oncol"},{"key":"2019111614154465400_B9","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"2019111614154465400_B10","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","article-title":"Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.","volume":"14","author":"Czuczman","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2019111614154465400_B11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","article-title":"Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.","volume":"14","author":"Olejniczak","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2019111614154465400_B12","doi-asserted-by":"crossref","first-page":"10556","DOI":"10.1158\/0008-5472.CAN-07-1811","article-title":"In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab.","volume":"67","author":"Macor","year":"2007","journal-title":"Cancer Res"},{"key":"2019111614154465400_B13","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1080\/10428190701647879","article-title":"CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.","volume":"48","author":"Cruz","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2019111614154465400_B14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1349-7006.2006.00139.x","article-title":"Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.","volume":"97","author":"Terui","year":"2006","journal-title":"Cancer Sci"},{"key":"2019111614154465400_B15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","article-title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines.","volume":"30","author":"Takei","year":"2006","journal-title":"Leuk Res"},{"key":"2019111614154465400_B16","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"key":"2019111614154465400_B17","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.2003.06.012","article-title":"Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance.","volume":"21","author":"Bannerji","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111614154465400_B18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"key":"2019111614154465400_B19","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"2019111614154465400_B20","first-page":"3916","article-title":"CD20-negative relapse in B-cell lymphoma after treatment with rituximab.","volume":"16","author":"Kinoshita","year":"1998","journal-title":"J Clin Oncol"},{"key":"2019111614154465400_B21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2141.1999.01608.x","article-title":"Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab.","volume":"106","author":"Schmitz","year":"1999","journal-title":"Br J Haematol"},{"key":"2019111614154465400_B22","first-page":"611","article-title":"Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.","volume":"5","author":"Davis","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2019111614154465400_B23","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1080\/1042819021000040044","article-title":"Recurrent B-cell neoplasms after rituximab therapy: an immunophenotypic and genotypic study.","volume":"43","author":"Chu","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"2019111614154465400_B24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1067\/mjd.2002.108490","article-title":"CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.","volume":"46","author":"Massengale","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2019111614154465400_B25","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","article-title":"Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.","volume":"119","author":"Kennedy","year":"2002","journal-title":"Br J Haematol"},{"key":"2019111614154465400_B26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00277-003-0694-1","article-title":"CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.","volume":"82","author":"Alvaro-Naranjo","year":"2003","journal-title":"Ann Hematol"},{"key":"2019111614154465400_B27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1034\/j.1600-0560.2003.00078.x","article-title":"Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.","volume":"30","author":"Clarke","year":"2003","journal-title":"J Cutan Pathol"},{"key":"2019111614154465400_B28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1034\/j.1600-0609.2003.00007.x","article-title":"Loss of CD20 expression in relapsed lymphomas after rituximab therapy.","volume":"70","author":"Haidar","year":"2003","journal-title":"Eur J Haematol"},{"key":"2019111614154465400_B29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.0303-6987.2005.00305.x","article-title":"The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.","volume":"32","author":"Rawal","year":"2005","journal-title":"J Cutan Pathol"},{"key":"2019111614154465400_B30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1177\/039463200601900218","article-title":"Bone marrow histopathological and molecular changes of small B-cell lymphomas after rituximab therapy: comparison with clinical response and patients outcome.","volume":"19","author":"Goteri","year":"2006","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2019111614154465400_B31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3324\/haematol.10255","article-title":"Re-occurrence of the CD20 molecule expression subsequent to CD20-negative relapse in diffuse large B-cell lymphoma.","volume":"92","author":"Ferreri","year":"2007","journal-title":"Haematologica"},{"key":"2019111614154465400_B32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1532\/IJH97.07028","article-title":"Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy.","volume":"86","author":"Tomita","year":"2007","journal-title":"Int J Hematol"},{"key":"2019111614154465400_B33","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111614154465400_B34","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111614154465400_B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2005.09.008","article-title":"Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene.","volume":"169","author":"Ninomiya","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"2019111614154465400_B36","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbrc.2006.05.047","article-title":"Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARalpha as a component of the N-CoR co-repressor complex to repress transcription in vivo.","volume":"345","author":"Atsumi","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"2019111614154465400_B37","doi-asserted-by":"crossref","first-page":"30788","DOI":"10.1074\/jbc.M303309200","article-title":"Fusion protein of retinoic acid receptor alpha with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo.","volume":"278","author":"Tomita","year":"2003","journal-title":"J Biol Chem"},{"key":"2019111614154465400_B38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature02625","article-title":"Epigenetics in human disease and prospects for epigenetic therapy.","volume":"429","author":"Egger","year":"2004","journal-title":"Nature"},{"key":"2019111614154465400_B39","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrd1930","article-title":"Epigenetic therapy of cancer: past, present and future.","volume":"5","author":"Yoo","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"2019111614154465400_B40","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial.","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"2019111614154465400_B41","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1182\/blood.V90.10.3984","article-title":"PU.1\/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes.","volume":"90","author":"Himmelmann","year":"1997","journal-title":"Blood"},{"key":"2019111614154465400_B42","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1182\/blood-2008-01-133108","article-title":"Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.","volume":"113","author":"Lapalombella","year":"2008","journal-title":"Blood"},{"key":"2019111614154465400_B43","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1182\/blood-2006-04-014639","article-title":"The epitope recognized by rituximab.","volume":"108","author":"Binder","year":"2006","journal-title":"Blood"},{"key":"2019111614154465400_B44","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1038\/sj.onc.1210365","article-title":"Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo\/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions.","volume":"26","author":"Bonavida","year":"2007","journal-title":"Oncogene"},{"key":"2019111614154465400_B45","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies.","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"2019111614154465400_B46","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1093\/hmg\/ddi113","article-title":"Cancer epigenetics.","volume":"14","author":"Laird","year":"2005","journal-title":"Hum Mol Genet"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/20\/4885\/1484016\/zh802009004885.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/113\/20\/4885\/1484016\/zh802009004885.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T14:15:59Z","timestamp":1573913759000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/113\/20\/4885\/116482\/Downregulation-of-CD20-expression-in-Bcell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,14]]},"references-count":46,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2009,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-08-175208","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1161332.621832","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,14]]}}}